Skip to main content

Advertisement

SpringerLink
Log in

Pneumatosis intestinalis and imatinib mesylate

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Coriat R, Ropert S, Mir O et al (2011) Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 29:1090–1093

    Article  CAS  PubMed  Google Scholar 

  2. Shinagare AB, Howard SA, Krajewski KM, Zukotynski KA, Jagannathan JP, Ramaiya NH (2012) Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 199:1259–1265

    Article  PubMed  Google Scholar 

  3. Viswanathan C, Bhosale P, Ganeshan DM, Truong MT, Silverman P, Balachandran A (2012) Imaging of complications of oncological therapy in the gastrointestinal system. Cancer Imaging 12:163–172

    Article  PubMed Central  PubMed  Google Scholar 

  4. Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96

    Article  PubMed  Google Scholar 

  5. Kashima T, Ohno Y, Tachibana M (2012) Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. Int J Urol 19:1041–1042

    Article  PubMed  Google Scholar 

  6. Choi YA, Sim EH, Lee KE et al (2013) A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma. Korean J Gastroenterol 61:347–350

    Article  PubMed  Google Scholar 

  7. Jarkowski A 3rd, Hare R, Francescutti V, Wilkinson N, Khushalani N (2011) Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res 31:3429–3432

    PubMed  Google Scholar 

  8. Vijayakanthan N, Dhamanaskar K, Stewart L et al (2012) A review of pneumatosis intestinalis in the setting of systemic cancer treatments, including tyrosine kinase inhibitors. Can Assoc Radiol J 63:312–317

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Haematology, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland

    Ciara O’Rafferty, Fiona McElligott, Lorna Storey, Aengus O’Marcaigh & Owen Smith

  2. Trinity College Dublin, Crumlin, Dublin, Ireland

    Aengus O’Marcaigh & Owen Smith

Authors
  1. Ciara O’Rafferty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fiona McElligott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorna Storey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aengus O’Marcaigh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Owen Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ciara O’Rafferty.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Rafferty, C., McElligott, F., Storey, L. et al. Pneumatosis intestinalis and imatinib mesylate. Ann Hematol 93, 1783–1784 (2014). https://doi.org/10.1007/s00277-014-2051-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2051-y

Keywords

Search

Navigation